82 citations
,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
9 citations
,
March 2022 in “Journal of radiation research” Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.
The patch effectively promotes hair growth for alopecia areata without pain.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
32 citations
,
April 2011 in “Journal of the American Academy of Dermatology” Erlotinib may cause scarring hair loss.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
5 citations
,
January 2016 in “International Journal of Trichology” Erlotinib can cause hair loss and texture changes.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
3 citations
,
May 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
Ubiquitination of the insulin receptor regulates collagen secretion in human skin.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
1 citations
,
November 2024 in “Saudi Pharmaceutical Journal” Adding baricitinib will increase costs but offers more treatment options for alopecia areata.
20 citations
,
May 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Etanercept effectively treated a severe skin condition when other treatments failed.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
January 2026 in “RSC Advances” 52 citations
,
February 2003 in “Archives of dermatology” 9-cis-retinoic acid showed some effectiveness in treating AIDS-related Kaposi sarcoma but had significant side effects at higher doses.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
October 2025 in “Clinical Chemistry” Juniperus communis extract enhances the effectiveness of oral cancer treatment when combined with chemotherapy.
November 2025 in “Journal of Investigative Dermatology” Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
8 citations
,
January 2019 in “Annals of Dermatology” Bilobetin may help reduce acne by decreasing sebum production.
1 citations
,
May 2025 in “Natural Products and Bioprospecting” PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.
January 2025 in “Biochemical Pharmacology” Peficitinib can turn human fibroblasts into cells that help grow hair.
July 2025 in “Jurnal Farmasi Sains dan Praktis” Most adverse reactions to the treatment were mild, with nausea being the most common.
32 citations
,
March 2018 in “Neoplasia” Nephronectin is linked to worse breast cancer outcomes and helps cancer spread.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.